Patrick Hsu: A New DNA Editing Technology Reported In Science Magazine
Patrick Hsu, Co-Founder of Arc Institute, posted on LinkedIn:
”Today in Science Magazine, we report a new DNA editing technology to seamlessly write massive changes into the right place in the human genome.
The reason gene editing hasn’t transformed human health is that current gene editing technologies like CRISPR are very limited.
The problem with CRISPR is that it cuts up your DNA, and then hopes that unreliable cellular DNA repair will make the wanted edit.
famously called it genome vandalism. More precise versions of CRISPR only edit less than 100 bases – often only a single base. Therefore, it’s not suited to make large changes safely.
However, most diseases are not the result of mutations in one location. Instead, their causes are spread all across the 3 billion base pairs in the genome.
We found bridge RNAs in bacterial “jumping genes” that allow us to make safe and arbitrary changes (insert, cut out, or flip) to every nucleotide within (up to) a 1 million bp sequence in your DNA.
In the paper, we show that we can correct the disease-causing DNA repeats that cause Friedreich’s ataxia (which is a rare neurological disease). The same approach could be applied to Huntington’s and other repeat expansion disorders.
This work was a wonderful collaboration with my Arc Institute cofounder Silvana Konermann and led by the indefatigable Nicholas Perry, alongside our amazing bridge editing team: Liam Bartie, Dhruva Katrekar, Gabriel Gonzalez, Matthew Durrant, James Pai, Alison Fanton, Juliana Martins, Masahiro Hiraizumi, Chiara Ricci-Tam, and Hiroshi Nishimasu”
Read the full article here.
Title: Megabase-scale human genome rearrangement with programmable bridge recombinases
Authors: Nicholas T. Perry, Liam J. Bartie, Dhruva Katrekar, Gabriel A. Gonzalez, Matthew G. Durrant, James J. Pai, Alison Fanton, Juliana Q. Martins, Masahiro Hiraizumi, Chiara Ricci-Tam, Hiroshi Nishimasu, Silvana Konermann, Patrick D. Hsu
Stay updated with Hemostasis Today.
-
Jul 21, 2026, 15:02Sham Zamil: The Role of ABO Compatibility in Platelet Pooling
-
Jul 21, 2026, 13:43Dima Shulkin: Assessing AI-Driven Blood Test Screening for Colorectal Cancer
-
Jul 21, 2026, 13:24Benoit Mores: National Initiative Targets Better Cardiovascular Outcomes
-
Jul 21, 2026, 13:10Paolo Zamboni: Chronic Cerebrospinal Venous Insufficiency Hypothesis in Multiple Sclerosis
-
Jul 21, 2026, 13:05Danai Poutakidou։ The Diagnostic Pitfalls of Unexpected PT/INR Prolongation
-
Jul 21, 2026, 13:00Kefah Mokbel: Beyond Thromboprophylaxis – Enoxaparin’s Emerging Anticancer Signal
-
Jul 21, 2026, 12:56Emmanuel Velazquez-Alvarez: Bridging Innovation and Clinical Practice
-
Jul 21, 2026, 12:53Sandrine Bouteille: A Milestone Presentation at ISTH 2026
-
Jul 21, 2026, 12:40Kalled Musallam: A Comprehensive Review of Thalassemia